|
|
CONSUMER NEWS
RECALLS
COMPLAINT FORM
SCAM ALERTS
Small Claims Guide Class Actions Lemon Laws FAQ Newsletters |
|
|
![]() |
MS Drug Tysabri Pulled After Death |
|||||
|
February 28, 2005
The companies are suspending supply of Tysabri from commercial distribution and have advised physicians to suspend dosing of the drug until further notification. In addition, the companies have suspended dosing in all clinical trials. In a joint statement, the two pharmaceutical companies said the decision is based on very recent reports of two serious adverse events that have occurred in patients treated with Tysabri in combination with Avonex in clinical trials. These events involve one fatal, confirmed case and one suspected case of progressive multifocal leukoencephalopathy, a rare and frequently fatal demyelinating disease of the central nervous system. Both patients received more than two years of Tysabri therapy in combination with Avonex. The companies said their actions have been taken in consultation with U.S. Food and Drug Administration (FDA). Worldwide regulatory agencies are also being kept informed. The companies said they will work with clinical investigators to evaluate Tysabri-treated patients and will consult with leading experts to better understand the possible risk of PML. The outcome of these evaluations will be used to determine possible re-initiation of dosing in clinical trials and future commercial availability. "Our ongoing commitment to MS patients has led us to take these steps," said Burt Adelman, MD, executive vice president, Development, Biogen Idec. "Because we believe in the promising therapeutic benefit of Tysabri, we are working to evaluate this situation thoroughly and expeditiously. While we work through this matter, we must place patient safety above all other considerations." In total, approximately 3,000 patients have been treated with Tysabri in clinical trials of MS, Crohn's disease, and rheumatoid arthritis. To date, the companies said they have received no reports of PML in MS patients receiving Tysabri monotherapy or in patients with Crohn's disease or rheumatoid arthritis in TYSABRI clinical trials. Biogen Idec has received no reports of PML in patients treated with AVONEX alone, a product that has been on the market since 1996. Report Your Experience
|
|||||
Back to the top | |
||||||
Advertisement
|
|
||||
|
AUTOMOTIVE Dealers Manufacturers Service Extended Warranties Lemon Laws Recalls Tires Transporters FAMILY Aging Children, Parenting Recalls Dating Education Entertainment Pets Weddings |
FINANCE Annuities Banks Credit Cards Debt Collection Debt Counseling Insurance Investing Loans Mortgages Payday Loans Student Loans Tax Prep HEALTH Drugs, Pharmacies Health Clubs Hearing Care Hospitals Nursing Homes Nutrition, Diets Vision Care Weight Loss |
HOMEOWNERS & RENTERS Appliances Cookware Furniture Home Improvements Lawn & Garden Movers Pools & Spas Realtors, Rental Agents Recalls Utilities ELECTRONICS Cable TV/DBS Cameras Cell Phones Computers Home Electronics Internet Access Local Phone Service Long Distance VoIP |
SHOPPING In-Home Online Retail Stores Sporting Goods Supermarkets Telemarketers TRAVEL Airlines Bus Lines Car Rental Cruises Hotels Travel Agents Trains RESOURCES Class Actions Complaint Form Small Claims Guide Lemon Laws |
CONSUMER NEWS Latest News Automotive Telecom Financial Health Homeowners Scams Seniors Travel More ... RECALLS Automotive Children's Products Drugs Food Household Products Sporting Goods ABOUT US FAQ Privacy Policy Advertise With Us Newsroom Syndication Terms of Use |
Terms of Use Your use of this site constitutes acceptance of the Terms of Use
Copyright © 2003-2008 ConsumerAffairs.com Inc. All Rights Reserved. The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission. |
|